Upregulated long noncoding RNAs LINC02163 and FEZF1-AS1 exert oncogenic roles in colorectal cancer

Abstract

A growing number of evidence has revealed that aberrantly expressed long noncoding RNAs (lncRNAs) are involved in the development of a variety of malignancies, including colorectal cancer (CRC). However, the clinical relevance of most lncRNAs and their potential biological functions in CRC remains poorly understood. The aim of this study was to identify the key lncRNAs related to patient prognosis as well as their biological function and underlying mechanism in CRC. Therefore, five independent datasets containing CRC and normal tissue RNA sequencing, microarray data and the corresponding clinical data from The Cancer Genome Atlas and Gene Expression Omnibus were screened. Hundreds of significantly differentially expressed lncRNAs in CRC were determined, and Kaplan–Meier analyses revealed that some of these lncRNAs were related to the overall survival and progression-free survival of patients with CRC, such as RP11-108K3.2, FOXD3-AS1, H19 and AP001469.9. Among these dysregulated lncRNAs, LINC02163 and FEZF1-AS1 were significantly upregulated in CRC tissues, suggesting that they may have oncogenic roles in CRC. Furthermore, loss of function assays revealed that downregulation of LINC02163 and FEZF1-AS1 impaired CRC cell proliferation. In addition, RNA Immunoprecipitation and Chromatin Immunoprecipitation assays determined that FEZF1-AS1 regulates CRC cell growth via interacting with LSD1 and repressing KLF2 expression. Collectively, hundreds of dysregulated lncRNAs and their associated biological roles identified in this study may provide potentially useful biomarkers and therapeutic targets for CRC.

Identification of a novel lncRNA prognostic signature and analysis of functional lncRNA AC115619.1 in hepatocellular carcinoma

“…Among the six lncRNAs in the prognostic model, LINC02163 and CASC9 were found to be upregulated in various cancers including HCC. LINC02163 and CASC9 were closely associated with the patient’s survival and acted as a candidate prognostic biomarker with their significant values ( Dong et al, 2018 ; Qin et al, 2020 ; Qi et al, 2021 ; Tian et al, 2021 ). LINC02362 and AC008549.1 were identified to be tumor-inhibitory lncRNAs and contributed to the patient’s survival of HCC, while the lncRNA AC008549.1 was classified as a pyroptosis-related signature ( Wang et al, 2022 ; Li et al, 2022 ).…”

Emerging Roles and Mechanisms of lncRNA FOXD3-AS1 in Human Diseases

“…A series of functional experiments in vitro and in vivo have validated the oncogenic property of FOXD3-AS1 in colon cancer through of the regulation of cell proliferation, migration, invasion, and apoptosis. However, Tian Y et al has also demonstrated that low expression of FOXD3-AS1 in colon cancer patients is associated with worse overall survival (93). Therefore, more research is needed to clarify the specific role of FOXD3-AS1 in colon cancer.…”

LincRNAs and snoRNAs in Breast Cancer Cell Metastasis: The Unknown Players

“…(J) Linc02163: Among other lincRNAs found to be deregulated in cancer, Linc02163 was recently shown to play a role in colorectal and breast cancer [ 76 , 77 ]. Linc02163 is located on chromosome 5q21.2 and it was found to be upregulated in breast cancer tissues compared to adjacent normal tissues with the findings being verified in four different breast cancer cell lines (SKBR3, MDA-MB-231, MCF-7, and BT-474) as compared to human immortalized breast epithelial cell line MCF-10A [ 77 ].…”